CLCS — Cell Source Share Price
0.000.00%
Last trade - 00:00- $13.54m
- -$0.30m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cell Source, Inc. is a cell therapy company focused on immunotherapy. The Company is primarily focused on the development of immune system management technology (Veto Cell technology). Its lead prospective product is its Veto Cell immune system management technology. Its Veto Cell technology is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is in pre-clinical phase, and its data shows that it provides results in allogeneic (donor-derived) hematopoietic stem cell transplantation (HSCT) by allowing for haploidentical stem cell transplants under a mild conditioning regimen. Its product pipeline includes chimeric antigen receptor (CAR) T-cell therapies, which include VETO CAR-T (with or without HSCT) for B-cell malignancies, Veto Cell kidney transplants, VETO CAR-T for solid tumors, Veto Cell liver transplants, and Veto HSCT for non-malignant disorders. The Company's wholly owned subsidiary is Cell Source Limited (CSL).
Directors
- Dennis Brown CHM (72)
- Itamar Shimrat CEO (62)
- Darlene Soave DRC (77)
- David Zolty DRC (70)
- Ben Friedman IND (61)
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- June 6th, 2012
- Public Since
- January 14th, 2014
- No. of Shareholders
- 213
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 43,468,184
- Address
- 57 West 57Th Street, Suite 400, NEW YORK, 10019
- Web
- https://cell-source.com/
- Phone
- +1 6466127554
- Auditors
- Marcum LLP
Upcoming Events for CLCS
Q1 2025 Cell Source Inc Earnings Release
Q2 2025 Cell Source Inc Earnings Release
Similar to CLCS
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
What is the Cell Source share price?
As of Today at 19:51 UTC, shares in Cell Source are trading at $0.31. This share price information is delayed by 15 minutes.
How has the Cell Source share price performed this year?
Shares in Cell Source last closed at $0.31 and the price had moved by +155650% over the past 365 days. In terms of relative price strength the Cell Source share price has outperformed the S&P500 Index by +144322.64% over the past year.
What are the analyst and broker recommendations for Cell Source?
There is no consensus recommendation for this security.
Find out moreWhat is the Cell Source dividend yield?
Cell Source does not currently pay a dividend.
Does Cell Source pay a dividend?
Cell Source does not currently pay a dividend.
When does Cell Source next pay dividends?
Cell Source does not currently pay a dividend.
How do I buy Cell Source shares?
To buy shares in Cell Source you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cell Source?
As of the previous close price of $0.31, shares in Cell Source had a market capitalisation of $13.54m.
Where are Cell Source shares listed?
Here are the trading details for Cell Source:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: CLCS
What kind of share is Cell Source?
Based on an overall assessment of its quality, value and momentum Cell Source is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cell Source share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Cell Source share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cell Source. Over the past six months, its share price has underperformed the S&P500 Index by -54.74%.
As of the last closing price of $0.31, shares in Cell Source were trading -22.43% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cell Source PE Ratio?
The Cell Source PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.31.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cell Source?
Cell Source's management team is headed by:
- Dennis Brown - CHM
- Itamar Shimrat - CEO
- Darlene Soave - DRC
- David Zolty - DRC
- Ben Friedman - IND